Brexit: Much Ado About Nothing?
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed…
This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities…
What is VR and why should healthcare and pharmaceutical companies take note? VR (Virtual Reality) places the user into a virtual world. VR differs from Augmented Reality (AR), which sets…
In a pharmaceutical environment faced with stiffening regulatory regimes, and where mergers and acquisitions become more commonplace, GSK’s diversifications and growth model have long come into question. Historically, Big Pharma…
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing nationwide parenting chaos. Executives from China’s second largest pharmaceutical company, ChangSheng biotechnology (Changsheng literally translates…
Portugal has forged a name for itself in terms of early adoption of new technology and ideas; making the country a prime destination for clinical trials as well as a…
After completing Phase II of clinical trials, Biogen and Eisai’s new candidate drug for Alzheimer’s Disease is showing strong potential in a field where research has met relentless challenges and…
By developing the first real-time AI system for use in operating rooms, a British medtech start-up is helping push forward the quality and precision of surgical care, as well as…
The last few years have witnessed the advent of a highly disruptive business model within the heart of the pharma world that fundamentally reconsiders the manner in which R&D is…
In the latest in a wave of Big Pharma companies retreating from the field of antibiotics, Novartis has decided to drop its antibacterial and antiviral early-stage research programs, laying off…
See our Cookie Privacy Policy Here
